DISCOVER
DIAGNOSE
DEFEND

oncquest laboratories

Uncover the tumor`s hidden biology…

MammaPrint+BluePrint

Interrogates critical genomic pathways to metastasis & guides on therapy selection in Breast Cancer



MammaPrint FDA cleared and ASCO recommended

33 laboratories, 200 Collection Centres &1300 + Service Associates

Web: www.oncquest.net Oncquestlaboratories

MammaPrint + BluePrint guide adjuvent treatment decision making for patients with early stage Breast cancer

MammaPrint

- FDA cleared and CE marked, recommended by ASCO for use in lymph node-positive and lymph node-negative patients
- Clear metastatic risk stratification, no ambiguity of an 'intermediate' recurrence risk, just binary Low or High risk result
- Result unaffected by clinico-pathological scoring
- Supported by the highest level of clinical evidence from the landmark MINDACT trial

BluePrint

- Molecular subtyping into Luminal-type, HER2/neu type, and Basal-type to help inform treatment decisions
- CE marked, has been shown to recassify up to 22% of breast cancers compared to conventionl immunohistochemistry(IHC) and fluorescence in situ hybridization(FISH) subtyping

References: Whitworth P, et al.Ann Surg Oncol.2014 oct;21(10):3261-7

MINDACT - A unique, independent study provides the highest level of evidence to support the clinical utility of MammaPrint

MINDACT - Microarray in Node- Negative and 1 to 3 Positive Lymph Node Disease May Avoid Chemotherapy

- MammaPrint Low Risk patients had no statistical benefit of chemotherapy with a 94.7% five-year Distant Metastasis Free Survival (DMFS) without chemotherapy. Of 3,356 clinical high risk patients, 46% were reclassified as MammaPrint Low Risk and could avoid chemotherapy without significant compromising their outcome.
- Hormone receptor positive and negative patients enrolled in the trial
- Randomized, prospective trial

References: F. Cardoso et al ; 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer - New England Journal of Medicine; August 25, 2016 vol. 375 no. 8

Test Details

Test Code	Test Name	Technique	Specimen	TAT / Reported on
SMO10242	MammaPrint + BluePrint Combination	Molecular Array	Formalin-fixed paraffin-embedded tissue block or 10 unstained slides with a 5 micron section on each slide. Must contain at least 30% invasive tumor.	18 working days